Monday, December 2, 2019
Havana.- The Cuban healthcare system contemplates the administration of the Heberbiovac HB vaccine, which prevents Hepatitis B in the country.
The vaccine, developed by the Genetic Engineering and Biotechnology Center (CIGB) contributes to reducing the incidence of that disease in Cuba, where no cases of hepatitis B have been reported in children from zero to 15 years of age since 2007.
The vaccine, which is obtained from the surface antigen of Hepatitis B, is administered once in the first days after childbirth and all Cuban infants are immunized against that disease.
Along with this, data are collected on the behavior of a new therapeutic vaccine Heber Nasvac to treat adult patients with chronic infection by the Hepatitis B virus.
The aim is to reactivate the immune system so that the individual can bring the virus under control and reduce it to levels that do not lead to liver cirrhosis.